Long-term Oncologic Outcomes of 1188 Tis-T2 Glottic Cancers Treated by Transoral Laser Microsurgery.

Abstract

To evaluate long-term disease-specific survival (DSS) and organ preservation (OP) rates in patients affected by Tis-T2 glottic squamous cell carcinoma (SCC) treated by carbon dioxide transoral laser microsurgery (CO₂ TOLMS). Single-center retrospective cohort study. Tertiary academic hospital. The study included patients treated by CO₂ TOLMS for Tis-T2 glottic SCC at the Department of Otorhinolaryngology-Head and Neck Surgery of the University of Brescia, Italy, from 1988 to 2018. The male:female ratio was 11.2:1, and the mean age was 64 years (range, 31-95). T categories were distributed as follows: 124 (10%) Tis, 646 (54%) T1a, 172 (15%) T1b, and 246 (21%) T2. Ten- and 20-year DSS rates were 97.6% and 96.3%, respectively, and 10- and 20-year OP rates were 94.7% and 93%. During the follow-up, 91% of patients were treated by CO₂ TOLMS alone, while the remaining needed adjunctive treatments. Assessing the impact of multiple sessions of CO₂ TOLMS, DSS showed no significant difference in terms of patients treated by 1, 2, or >2 procedures. Conversely, patients treated by >2 sessions of CO₂ TOLMS showed a significantly worse OP rate. Our series validates CO₂ TOLMS as a long-term treatment strategy for early glottic SCC. Salvage CO₂ TOLMS provided optimal results in terms of DSS and OP in patients with recurrence after previous transoral surgery.